Type 2 diabetes mellitus and erectile dysfunction

Journal of Sexual Medicine

Volumn 6, Issue 4, 2009, Pages 916-926

  Hidalgo Tamola, Josephine ^a   Chitaley, Kanchan ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes; Endothelial dysfunction; Epidemiology; Erectile dysfunction; Hypogonadism; Neuropathy; Oxidative stress; Smooth muscle dysfunction; Type 2 diabetes mellitus

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ARGININE; BRETYLIUM TOSYLATE; CHELERYTHRINE; PHOSPHODIESTERASE V INHIBITOR; PIOGLITAZONE; PLACEBO; PROPIONYLCARNITINE; SILDENAFIL; TESTOSTERONE; TESTOSTERONE UNDECANOATE;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPOGONADISM; INFORMATION RETRIEVAL; LOW DRUG DOSE; MALE; MEDLINE; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONADRENERGIC NONCHOLINERGIC NERVE; NONHUMAN; OUTCOMES RESEARCH; OXIDATIVE STRESS; PENIS ERECTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTION; SMOOTH MUSCLE FIBER; VASODILATATION; VEIN OCCLUSION; ANIMAL; DISEASE MODEL; MUSCLE CONTRACTION; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PHYSIOLOGY; RAT; SMOOTH MUSCLE; VASCULAR ENDOTHELIUM; VASOCONSTRICTION;

ANIMALS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; ERECTILE DYSFUNCTION; HUMANS; HYPOGONADISM; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; OXIDATIVE STRESS; PERIPHERAL NERVOUS SYSTEM DISEASES; RATS; VASOCONSTRICTION;

EID: 63849091443     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2008.01116.x     Document Type: Review

References (62)

1. Impotence. NIH Consenus Statement. Am Fam Physician 1992;10:1-31.
2. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
3. Saigal CS, Wessells H, Pace J, Schonlau M, Wilt TJ. Predictors and prevalence of erectile dysfunction in a racially diverse population. Arch Intern Med 2006;166:207-12.
4. McCulloch DK, Campbell IW, Wu FC, Prescott RJ, Clarke BF. The prevalence of diabetic impotence. Diabetologia 1980;18:279-83.
5. Wessells H, Joyce GF, Wise M, Wilt TJ. Erectile dysfunction. J Urol 2007;177:1675-81.
6. Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: A randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999;281:421-6.
7. Penson DF, Latini DM, Lubeck DP, Wallace KL, Henning JM, Lue TF. Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database. Diabetes Care 2003;26:1093-9.
8. Centers for Disease Control and Prevention. National Diabetes Fact Sheet. 2007.
9. Saenz de Tejada I, Blanco R, Goldstein I, Azadzoi K, de las Morenas A, Krane RJ, Cohen RA. Cholinergic neurotransmission in human corpus cavernosum. I. Responses of isolated tissue. Am J Physiol 1988;254:H459-67.
10. Burnett AL, Nelson RJ, Calvin DC, Liu JX, Demas GE, Klein SL, Kriegsfeld LJ, Dawson VL, Dawson TM, Snyder SH. Nitric oxide-dependent penile erection in mice lacking neuronal nitric oxide synthase. Mol Med 1996;2:288-96.
11. Burnett AL. Nitric oxide regulation of penile erection: Biology and therapeutic implications. J Androl 2002;23:S20-6.
12. Burnett AL, Chang AG, Crone JK, Huang PL, Sezen SE. Noncholinergic penile erection in mice lacking the gene for endothelial nitric oxide synthase. J Androl 2002;23:92-7.
13. Hurt KJ, Musicki B, Palese MA, Crone JK, Becker RE, Moriarity JL, Snyder SH, Burnett AL. Akt-dependent phosphorylation of endothelial nitric-oxide synthase mediates penile erection. Proc Natl Acad Sci USA 2002;99:4061-6.
14. Wessells H, Teal TH, Engel K, Sullivan CJ, Gallis B, Tran KB, Chitaley K. Fluid shear stress-induced nitric oxide production in human cavernosal endothelial cells: Inhibition by hyperglycaemia. BJU Int 2006;97:1047-52.
15. Saenz de Tejada I, Moroukian P, Tessier J, Kim JJ, Goldstein I, Frohrib D. Trabecular smooth muscle modulates the capacitor function of the penis. Studies on a rabbit model. Am J Physiol 1991;260:H1590-5.
16. Andersson KE. Erectile physiological and pathophysiological pathways involved in erectile dysfunction. J Urol 2003;170:S6-13; discussion S13-4.
17. Chitaley K, Webb RC, Mills TM. RhoA/Rho-kinase: A novel player in the regulation of penile erection. Int J Impot Res 2001;13:67-72.
18. Takahashi R, Nishimura J, Hirano K, Naito S, Kanaide H. Modulation of Ca2+ sensitivity regulates contractility of rabbit corpus cavernosum smooth muscle. J Urol 2003;169:2412-6.
19. Kasiske BL, O'Donnell MP, Keane WF. The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension 1992;19:I110-5.
20. Guberski DL, Butler L, Manzi SM, Stubbs M, Like AA. The BBZ/Wor rat: clinical characteristics of the diabetic syndrome. Diabetologia 1993;36:912-9.
21. Vernet D, Cai L, Garban H, Babbitt ML, Murray FT, Rajfer J, Gonzalez-Cadavid NF. Reduction of penile nitric oxide synthase in diabetic BB/WORdp (type I) and BBZ/WORdp (type II) rats with erectile dysfunction. Endocrinology 1995;136:5709-17.
22. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 1992;41:1422-8.
23. Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN. Diet-induced type II diabetes in C57BL/6J mice. Diabetes 1988;37:1163-7.
24. Xie D, Odronic SI, Wu F, Pippen A, Donatucci CF, Annex BH. Mouse model of erectile dysfunction due to diet-induced diabetes mellitus. Urology 2007;70:196-201.
25. Sharma K, McCue P, Dunn SR. Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol 2003;284:F1138-44.
26. Srinivasan K, Ramarao P. Animal models in type 2 diabetes research: An overview. Indian J Med Res 2007;125:451-72.
27. De Angelis L, Marfella MA, Siniscalchi M, Marino L, Nappo F, Giugliano F, De Lucia D, Giugliano D. Erectile and endothelial dysfunction in Type II diabetes: A possible link. Diabetologia 2001;44:1155-60.
28. Luttrell IP, Swee M, Starcher B, Parks WC, Chitaley K. Erectile dysfunction in the type II diabetic db/db mouse: Impaired venoocclusion with altered cavernosal vasoreactivity and matrix. Am J Physiol Heart Circ Physiol 2008;294:H2204-11.
29. Wingard C, Fulton D, Husain S. Altered penile vascular reactivity and erection in the Zucker obese-diabetic rat. J Sex Med 2007;4:348-62; discussion 362-43.
30. Jesmin S, Sakuma I, Salah-Eldin A, Nonomura K, Hattori Y, Kitabatake A. Diminished penile expression of vascular endothelial growth factor and its receptors at the insulin-resistant stage of a type II diabetic rat model: A possible cause for erectile dysfunction in diabetes. J Mol Endocrinol 2003;31:401-18.
31. Musicki B, Palese MA, Crone JK, Burnett AL. Phosphorylated endothelial nitric oxide synthase mediates vascular endothelial growth factor-induced penile erection. Biol Reprod 2004;70:282-9.
32. Newsholme P, Haber EP, Hirabara SM, Rebelato EL, Procopio J, Morgan D, Oliveira-Emilio HC, Carpinelli AR, Curi R. Diabetes associated cell stress and dysfunction: Role of mitochondrial and non-mitochondrial ROS production and activity. J Physiol 2007;583:9-24.
33. Yan SF, Ramasamy R, Schmidt AM. Mechanisms of disease: Advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab 2008;4:285-93.
34. Morano S, Gatti A, Mandosi E, Tiberti C, Fallarino M, Cipriani R, Buchetti B, Gandini L, Sgro P, Jannini EA, Lenti L, Lenzi A. Circulating monocyte oxidative activity is increased in patients with type 2 diabetes and erectile dysfunction. J Urol 2007;177:655-9.
35. Tagliabue M, Pinach S, Di Bisceglie C, Brocato L, Cassader M, Bertagna A, Manieri C, Pescarmona GP. Glutathione levels in patients with erectile dysfunction, with or without diabetes mellitus. Int J Androl 2005;28:156-62.
36. Hoogeveen EK, Kostense PJ, Jakobs C, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study. Circulation 2000;101:1506-11.
37. Jacobsen DW, Catanescu O, Dibello PM, Barbato JC. Molecular targeting by homocysteine: A mechanism for vascular pathogenesis. Clin Chem Lab Med 2005;43:1076-83.
38. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Bmj 2002;325:1202.
39. Demir T, Comlekci A, Demir O, Gulcu A, Calypkan S, Argun L, Secil M, Yepil S, Esen A. Hyperhomocysteinemia: A novel risk factor for erectile dysfunction. Metabolism 2006;55:1564-8.
40. Al-Hunayan A, Thalib L, Kehinde EO, Asfar S. Hyperhomocysteinemia is a risk factor for erectile dysfunction in men with adult-onset diabetes mellitus. Urology 2008;71:897-900.
41. Demir T, Comlekci A, Demir O, Gulcu A, Caliskan S, Argun L, Secil M, Yesil S, Esen A. A possible new risk factor in diabetic patients with erectile dysfunction: Homocysteinemia. J Diabetes Complications 2008 Apr 15 [Epub ahead of print].
42. Felix C, Gillis M, Driedzic WR, Paulson DJ, Broderick TL. Effects of propionyl-L-carnitine on isolated mitochondrial function in the reperfused diabetic rat heart. Diabetes Res Clin Pract 2001;53:17-24.
43. Morano S, Mandosi E, Fallarino M, Gatti A, Tiberti C, Sensi M, Gandini L, Buchetti B, Lenti L, Jannini EA, Lenzi A. Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: A double-blind, placebo-controlled study. Eur Urol 2007;52:1768-74.
44. Kovanecz I, Ferrini MG, Vernet D, Nolazco G, Rajfer J, Gonzalez-Cadavid NF. Pioglitazone prevents corporal veno-occlusive dysfunction in a rat model of type 2 diabetes mellitus. BJU Int 2006;98:116-24.
45. Wilcox R, Kupfer S, Erdmann E. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). Am Heart J 2008;155:712-7.
46. Carneiro FS, Giachini FR, Lima VV, Carneiro ZN, Leite R, Inscho EW, Tostes RC, Webb RC. Adenosine actions are preserved in corpus cavernosum from obese and type II diabetic db/db mouse. J Sex Med 2008;5:1156-66.
47. Chen Y, Li SX, Yao LS, Wang R, Dai YT. Valsartan treatment reverses erectile dysfunction in diabetic rats. Int J Impot Res 2007;19:366-70.
48. Colakoglu Z, Kutluay E, Ertekin C, Altay B, Killi R, Alkis A. Autonomic nerve involvement and venous leakage in diabetic men with impotence. BJU Int 1999;83:453-6.
49. Metro MJ, Broderick GA. Diabetes and vascular impotence: Does insulin dependence increase the relative severity? Int J Impot Res 1999;11:87-9.
50. Kapoor D, Malkin CJ, Channer KS, Jones TH. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf) 2005;63:239-50.
51. Corona G, Mannucci E, Petrone L, Ricca V, Balercia G, Mansani R, Chiarini V, Giommi R, Forti G, Maggi M. Association of hypogonadism and type II diabetes in men attending an outpatient erectile dysfunction clinic. Int J Impot Res 2006;18:190-7.
52. El-Sakka AI, Sayed HM, Tayeb KA. Type 2 diabetes-associated androgen alteration in patients with erectile dysfunction. Int J Androl 2007 Sep 18. [Epub ahead of print].
53. Kapoor D, Clarke S, Channer KS, Jones TH. Erectile dysfunction is associated with low bioactive testosterone levels and visceral adiposity in men with type 2 diabetes. Int J Androl 2007;30:500-7.
54. Corona G, Mannucci E, Petrone L, Balercia G, Paggi F, Fisher AD, Lotti F, Chiarini V, Fedele D, Forti G, Maggi M. NCEP-ATPIII-defined metabolic syndrome, type 2 diabetes mellitus, and prevalence of hypogonadism in male patients with sexual dysfunction. J Sex Med 2007;4:1038-45.
55. Zhang XH, Morelli A, Luconi M, Vignozzi L, Filippi S, Marini M, Vannelli GB, Mancina R, Forti G, Maggi M. Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum. Eur Urol 2005;47:409-16; discussion416.
56. Kalinchenko SY, Kozlov GI, Gontcharov NP, Katsiya GV. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 2003;6:94-9.
57. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000;321:405-12.
58. Romeo JH, Seftel AD, Madhun ZT, Aron DC. Sexual function in men with diabetes type 2: Association with glycemic control. J Urol 2000;163:788-91.
59. Yaman O, Akand M, Gursoy A, Erdogan MF, Anafarta K. The effect of diabetes mellitus treatment and good glycemic control on the erectile function in men with diabetes mellitus-induced erectile dysfunction: A pilot study. J Sex Med 2006;3:344-8.
60. Gazzaruso C, Solerte SB, Pujia A, Coppola A, Vezzoli M, Salvucci F, Valenti C, Giustina A, Garzaniti A. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: A potential protective role for statins and 5-phosphodiesterase inhibitors. J Am Coll Cardiol 2008;51:2040-4.
61. Ma RC, So WY, Yang X, Yu LW, Kong AP, Ko GT, Chow CC, Cockram CS, Chan JC, Tong PC. Erectile dysfunction predicts coronary heart disease in type 2 diabetes. J Am Coll Cardiol 2008;51:2045-50.
62. Gazzaruso C, Giordanetti S, De Amici E, Bertone G, Falcone C, Geroldi D, Fratino P, Solerte SB, Garzaniti A. Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation 2004;110:22-6.